What is Immuneering Corporation's (IMRX) StockRank?

MoatMap's StockRank for Immuneering Corporation (IMRX) is 16/100, with a Strong Sell signal. This is a composite score combining Quality (42), Value (40), and Momentum (22) factor ranks across MoatMap's 19,000+ stock universe.

Does Immuneering Corporation have an economic moat?

Immuneering Corporation (IMRX) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Immuneering Corporation a buy, hold, or sell?

MoatMap's current signal for Immuneering Corporation (IMRX) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Immuneering Corporation in?

Immuneering Corporation (IMRX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

IMRX

STRONG SELLREMOVE

Immuneering Corporation · Healthcare · United States · $327M · Avg Vol: $8M/d

StockRank

P/E (TTM)

—

ROE

-43.8%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Immuneering Corporation is an early-stage oncology biotech with high cash burn and no commercialized products, representing an unacceptable risk profile.

COMPANY DESCRIPTION

Immuneering Corporation is a clinical-stage oncology company focused on developing translational medicines that target the MAPK pathway to treat solid tumors. The company's competitive moat is anchored by its proprietary Disease-Canceling Technology (DCT) platform, which designs medicines to selectively target cancer cells while sparing healthy tissue. It operates as a specialized biotechnology player aiming to overcome drug resistance in oncology.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	316,952	0	0	0	—
EPS	-1.91	-1.88	-2.04	-1.27	—
Shares	26M	29M	31M	65M	+144.7%
Debt	5M	4M	4M	4M	-7.6%
Equity	110M	91M	41M	218M	25.8%
Op CF	-44M	-49M	-55M	-45M	—
Inv CF	42M	7M	26M	-89M	—
Fin CF	19,004	28M	5M	227M	—

PRICE (1M)-22.2%

SMA 50SMA 200

$4.19

RSI (14)

36.2

52W High

$10.08

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-26.8%24.6

ROE

-43.8%19.6

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-14.3%23.1

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.02x83.6

Current Ratio

32.45x98.3

Value

P/E (TTM)

—N/A

EV/EBITDA

-2.0x66.8

P/FCF

—N/A

P/B

1.3x71.3

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

42%14.0

RS 6M

-41%29.0

SMA 50/200

0.88x29.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-26%13.0

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$327M

P/E (Forward)

-3.1x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMRX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
IMRX	Immuneering Corporation(you)	$327M	16	STRONG SELL
REPL	Replimune Group, Inc.	$386M	16	STRONG SELL
RCKT	Rocket Pharmaceuticals, Inc.	$330M	21	SELL
CNTX	Context Therapeutics Inc.	$260M	16	STRONG SELL
FHTX	Foghorn Therapeutics Inc.	$251M	16	STRONG SELL
CHRS	Coherus Oncology, Inc.	$255M	17	STRONG SELL
RZLT	Rezolute, Inc.	$315M	21	SELL
DMAC	DiaMedica Therapeutics Inc.	$332M	10	STRONG SELL
MNPR	Monopar Therapeutics Inc.	$432M	18	STRONG SELL
TRDA	Entrada Therapeutics, Inc.	$265M	13	STRONG SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Immuneering Corporation (IMRX) — Stock Score Summary

Immuneering Corporation (IMRX) has a MoatMap StockRank of 16/100 based on Quality (42/100), Value (40/100), and Momentum (22/100) factor scores. The current signal is STRONG SELL. Immuneering Corporation is an early-stage oncology biotech with high cash burn and no commercialized products, representing an unacceptable risk profile.

Key Financial Metrics

Price	$4.19
Market Cap	$327M
P/E (Forward)	-3.13
Price/Book	1.31
Return on Equity	-43.8%
Return on Invested Capital	-26.8%
Debt/Equity	1.81
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-33M

Immuneering Corporation operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Immuneering Corporation’s (IMRX) StockRank?: MoatMap’s StockRank for Immuneering Corporation (IMRX) is 16/100, with a Strong Sell signal. It is a composite of Quality (42), Value (40), and Momentum (22) factor ranks across MoatMap’s 19,000+ stock universe.
Does Immuneering Corporation have an economic moat?: Immuneering Corporation (IMRX) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Immuneering Corporation a buy, hold, or sell?: MoatMap’s current signal for Immuneering Corporation (IMRX) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Immuneering Corporation in?: Immuneering Corporation (IMRX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).